Zurcher Kantonalbank Zurich Cantonalbank Buys 1,206 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 79,599 shares of the medical research company’s stock after acquiring an additional 1,206 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in IQVIA were worth $18,418,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. First American Trust FSB raised its holdings in IQVIA by 1.3% during the 4th quarter. First American Trust FSB now owns 35,198 shares of the medical research company’s stock worth $8,144,000 after buying an additional 461 shares during the period. Keel Point LLC acquired a new stake in IQVIA during the 4th quarter worth approximately $233,000. Mackenzie Financial Corp raised its holdings in IQVIA by 0.4% during the 4th quarter. Mackenzie Financial Corp now owns 41,728 shares of the medical research company’s stock worth $9,655,000 after buying an additional 178 shares during the period. Cullen Investment Group LTD. acquired a new stake in IQVIA during the 4th quarter worth approximately $4,442,000. Finally, Strs Ohio raised its holdings in IQVIA by 31.9% during the 4th quarter. Strs Ohio now owns 245,941 shares of the medical research company’s stock worth $56,905,000 after buying an additional 59,470 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

NYSE:IQV opened at $227.17 on Friday. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The firm has a fifty day simple moving average of $244.62 and a 200 day simple moving average of $221.41. The stock has a market capitalization of $41.23 billion, a PE ratio of 31.16, a P/E/G ratio of 2.20 and a beta of 1.50.

IQVIA (NYSE:IQV) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The business had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same period last year, the business earned $2.54 earnings per share. The firm’s revenue was up 3.5% on a year-over-year basis. On average, research analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

Insider Activity at IQVIA

In related news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have commented on the stock. Truist Financial raised their target price on shares of IQVIA from $286.00 to $297.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. SVB Leerink began coverage on shares of IQVIA in a report on Monday, February 26th. They set an “outperform” rating and a $290.00 target price on the stock. UBS Group lifted their price objective on shares of IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Finally, BTIG Research began coverage on shares of IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price objective on the stock. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.